Understanding how tumors interact with the immune system and resist treatment in bladder cancer
Tumor-Immune Interactions and Cisplatin Resistance in Bladder Cancer
['FUNDING_CAREER'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-10985089
This study is looking at how bladder cancer tumors hide from the immune system and resist a common chemotherapy drug, with the goal of finding new ways to help patients respond better to treatment.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10985089 on ClinicalTrials.gov |
What this research studies
This research investigates the interactions between bladder cancer tumors and the immune system, particularly focusing on how tumors evade immune responses and resist the chemotherapy drug cisplatin. The principal investigator, Dr. Filipe de Carvalho, aims to develop new therapeutic strategies that target immune-suppressive cells within the tumor microenvironment. By studying tumor-associated macrophages, which play a significant role in tumor growth and immune evasion, the research seeks to identify novel treatments that could enhance the effectiveness of existing therapies. Patients may benefit from advancements in treatment options that could improve their response to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer who are undergoing treatment or are resistant to current therapies.
Not a fit: Patients with non-bladder cancers or those who are not currently receiving treatment for bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bladder cancer, improving patient outcomes and survival rates.
How similar studies have performed: Previous research has shown promise in targeting immune cells in cancer treatment, indicating that this approach could lead to significant advancements in bladder cancer therapy.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DE CARVALHO, FILIPE — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: DE CARVALHO, FILIPE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer